534 results on '"Concin, Nicole"'
Search Results
202. Clinical Relevance of Dominant-Negative p73 Isoforms for Responsiveness to Chemotherapy and Survival in Ovarian Cancer: Evidence for a Crucial p53-p73 Cross-talk In vivo
- Author
-
Concin, Nicole, primary, Hofstetter, Gerda, additional, Berger, Astrid, additional, Gehmacher, Adriana, additional, Reimer, Daniel, additional, Watrowski, Rafal, additional, Tong, Dan, additional, Schuster, Eva, additional, Hefler, Lukas, additional, Heim, Kurt, additional, Mueller-Holzner, Elisabeth, additional, Marth, Christian, additional, Moll, Ute M., additional, Zeimet, Alain G., additional, and Zeillinger, Robert, additional
- Published
- 2005
- Full Text
- View/download PDF
203. Transdominant ΔTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitorsin Vivo
- Author
-
Concin, Nicole, primary, Becker, Kirsten, additional, Slade, Neda, additional, Erster, Susan, additional, Mueller-Holzner, Elizabeth, additional, Ulmer, Hanno, additional, Daxenbichler, Guenter, additional, Zeimet, Alain, additional, Zeillinger, Robert, additional, Marth, Christian, additional, and Moll, Ute M., additional
- Published
- 2004
- Full Text
- View/download PDF
204. Role of p53 in G2/M cell cycle arrest and apoptosis in response to γ-irradiation in ovarian carcinoma cell lines
- Author
-
Concin, Nicole, primary, Stimpfl, Margit, additional, Zeillinger, Christa, additional, Wolff, Uwe, additional, Hefler, Lukas, additional, Sedlak, Jan, additional, Leodolter, Sepp, additional, and Zeillinger, Robert, additional
- Published
- 2003
- Full Text
- View/download PDF
205. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, and GEICO Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Epithelial Ovarian Cancer
- Author
-
Harter, Philipp, Bogner, Gerhard, Chiva, Luis, Cibula, David, Concin, Nicole, Fotopoulou, Christina, Gonzalez-Martin, Antonio, Heinzelmann-Schwarz, Viola, Kridelka, Frederic, Mahner, Sven, Marmé, Frederik, Marth, Christian, Novák, Zoltán, Papadia, Andrea, Redecha, Mikuláš, Redondo, Andres, Schwameis, Richard, Sehouli, Jalid, Undurraga, Manuela, Van Gorp, Toon, and Vergote, Ignace
- Abstract
An international joint statement about the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer was published in 2016, warning about the uncritical use of HIPEC outside controlled studies. This statement has now been updated after the most recent literature was reviewed by the participating study groups and societies. HIPEC became a treatment option in patients with advanced colon cancer after positive results of a randomized trial comparing surgery and HIPEC versus palliative treatment alone. Although this trial did not compare the added value of HIPEC to surgery alone, HIPEC for the treatment of peritoneal metastases was in the subsequent years generalized to many other cancer types associated with peritoneal carcinomatosis including epithelial ovarian cancer (EOC). In the meantime, new evidence from prospective randomized trials specifically for EOC- patients emerged, with however contradicting results and several quality aspects that made the interpretation of their findings critical. Moreover, three additional trials in colorectal cancer failed to confirm the previously presumed survival benefit through the implementation of HIPEC in peritoneally disseminated colorectal cancers. Based on a still unclear and inconsistent landscape, the authors conclude that HIPEC should remain within the remit of clinical trials for EOC- patients. Available evidence is not yet sufficient to justify its broad endorsement into the routine clinical practice.
- Published
- 2023
- Full Text
- View/download PDF
206. p53 in Human Cancer — Somatic and Inherited Mutations and Mutation-independent Mechanisms.
- Author
-
Zouhair Atassi, M., Berliner, Lawrence J., Rowen Jui-Yoa Chang, Jörnvall, Hans, Kenyon, George L., Wittman-Liebold, Brigitte, Zambetti, Gerard P., Moll, Ute M., and Concin, Nicole
- Abstract
The p53 tumor suppressor protein plays a central role in maintaining genomic integrity. It does so by occupying a nodal point in the DNA damage control pathway. When cells are subjected to ionizing radiation or other mutagenic events, p53 mediates cell cycle arrest, senescence or programmed cell death (apoptosis). Furthermore, some evidence suggests that p53 plays a role in the recognition and repair of damaged DNA. p53 is a tetrameric transcription factor but also has transcription-independent proapoptotic functions. Conversely, disruption of the p53 response pathway strongly correlates with tumorigenesis. p53 is functionally inactivated by structural mutations, neutralization by viral products, cytoplasmic sequestration, and alterations in upstream regulators or downstream effectors in the vast majority of human cancers. p53-deficient mice have a highly penetrant tumor phenotype with over 90% tumor incidence within nine months. In some cancers direct physical evidence exists that identify the p53 gene as a target of known environmental carcinogens such as UV light and benzo[a]pyrene in cancers of the skin and lung. When p53 loss occurs, cells do not get repaired or eliminated but rather proceed to replicate damaged DNA, which results in more random mutations, gene amplifications, chromosomal rearrangements, and aneuploidy. In some experimental models, loss of p53 confers resistance to anticancer therapy due to loss of apoptotic competence. The translational potential of these discoveries are beginning to be tested in novel p53-based therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
207. The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma
- Author
-
Hefler, Lukas A., primary, Concin, Nicole, additional, Mincham, David, additional, Thompson, Jane, additional, Swarte, Nikkie B., additional, van Eijkeren, Marion A., additional, Sie-Go, Daisy M.D.S., additional, Hammond, Ian, additional, McCartney, Anthony J., additional, Tempfer, Clemens B., additional, and Speiser, Paul, additional
- Published
- 2001
- Full Text
- View/download PDF
208. p53-dependent radioresistance in ovarian carcinoma cell lines
- Author
-
Concin, Nicole, primary, Zeillinger, Christa, additional, Stimpfel, Margit, additional, Schiebel, Ingrid, additional, Tong, Dan, additional, Wolff, Uwe, additional, Reiner, Angelika, additional, Leodolter, Sepp, additional, and Zeillinger, Robert, additional
- Published
- 2000
- Full Text
- View/download PDF
209. Serum Concentrations of Tissue Polypeptide Antigen in Patients with Vulvar Intraepithelial Neoplasia and Vulvar Cancer
- Author
-
Hefler, Lukas, primary, Tempfer, Clemens, additional, Frischmuth, Katrin, additional, Maenner, Georg, additional, Concin, Nicole, additional, Sliutz, Gerhard, additional, Reinthaller, Alexander, additional, Leodolter, Sepp, additional, and Kainz, Christian, additional
- Published
- 2000
- Full Text
- View/download PDF
210. HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer -- a study.
- Author
-
Braicu, Elena Ioana, Luketina, Hrvoje, Richter, Rolf, Castillo-Tong, Dan Cacsire, Lambrechts, Sandrina, Mahner, Sven, Concin, Nicole, Mentze, Monika, Zeillinger, Robert, Vergote, Ignace, and Sehouli, Jalid
- Subjects
PROGNOSTIC tests ,OVARIAN cancer treatment ,OBSTETRICS ,CANCER chemotherapy ,CYTOREDUCTIVE surgery - Abstract
Purpose: Hypoxia is a common phenomenon encountered in solid cancers, leading to chemotherapy resistance and therefore to aggressiveness of the disease. The homeostatic response to hypoxia is mediated by hypoxia-inducible factor-1 (HIF-1). The aim of this study was to investigate the impact of HIF1α in patients with primary epithelial ovarian cancer. Methods: In this multicentric study, 275 patients with advanced primary epithelial ovarian cancer were included. All patients underwent cytoreductive surgery with maximal surgical effort and adjuvant platinum-based chemotherapy. HIF1α expression was analyzed in tissue lysates, using an enzyme-linked immunosorbent assay. Results: HIF1α was detected in 79.3% of the tissue samples. Patients with increased HIF1α expression (cutoff: 80 pg/mg protein) in tumoral tissue lysates were more likely to have less favorable survival. HIF1α (P=0.009, hazard ratio [HR] 2.505, 95% confidence interval [95% CI] 1.252-5.013) together with International Federation of Gynecology and Obstetrics (III versus IV) (P=0.013, HR 0.540, 95% CI 0.332-0.878), histology (P=0.007, HR 2.748, 95% CI 1.315-5.743), presence of peritoneal carcinomatosis (P=0.014, HR 2.176, 95% CI 1.170-4.046), residual tumor mass (P=0.017, HR 1.641, 95% CI 1.091-2.468), and response to platinum-based chemotherapy (P,0.001, HR 8.131, 95% CI 5.13-12.88) were independent prognosis factors for overall survival. The independent prognostic factors for progression- free survival were International Federation of Gynecology and Obstetrics stage (P=0.01), histological subtypes (P=0.016), and presence of peritoneal carcinomatosis (P,0.05). Conclusion: HIF1α overexpression in ovarian cancer is associated with poor overall survival, underlining the importance of hypoxia in this angiogenesis driven disease. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
211. Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients.
- Author
-
Dan Tong, Heinze, Georg, Pils, Dietmar, Wolf, Andrea, Singer, Christian F., Concin, Nicole, Hofstetter, Gerda, Schiebel, Ingrid, Rudas, Margaretha, and Zeillinger, Robert
- Subjects
BREAST cancer patients ,PROTEINS ,GENE expression ,ESTROGEN ,DISEASES in women - Abstract
Background: Gene expression of peripheral myelin protein 22 (PMP22) and the epithelial membrane proteins (EMPs) was found to be differentially expressed in invasive and non-invasive breast cell lines in a previous study. We want to evaluate the prognostic impact of the expression of these genes on breast cancer. Methods: In a retrospective multicenter study, gene expression of PMP22 and the EMPs was measured in 249 primary breast tumors by real-time PCR. Results were statistically analyzed together with clinical data. Results: In univariable Cox regression analyses PMP22 and the EMPs were not associated with disease-free survival or tumor-related mortality. However, multivariable Cox regression revealed that patients with higher than median PMP22 gene expression have a 3.47 times higher risk to die of cancer compared to patients with equal values on clinical covariables but lower PMP22 expression. They also have a 1.77 times higher risk to relapse than those with lower PMP22 expression. The proportion of explained variation in overall survival due to PMP22 gene expression was 6.5% and thus PMP22 contributes equally to prognosis of overall survival as nodal status and estrogen receptor status. Cross validation demonstrates that 5-years survival rates can be refined by incorporating PMP22 into the prediction model. Conclusions: PMP22 gene expression is a novel independent prognostic factor for disease-free survival and overall survival for breast cancer patients. Including it into a model with established prognostic factors will increase the accuracy of prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
212. Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium.
- Author
-
Obermayr, Eva, Braicu, Elena Ioana, Polterauer, Stephan, Loverix, Liselore, Concin, Nicole, Woelber, Linn, Mahner, Sven, Sehouli, Jalid, Van Gorp, Toon, Vergote, Ignace, Zeillinger, Robert, and Aust, Stefanie
- Subjects
EVALUATION of medical care ,RESEARCH ,ALBUMINS ,C-reactive protein ,DISEASE progression ,SURVIVAL ,OVARIAN tumors ,MULTIVARIATE analysis ,MEDICAL cooperation ,TRYPTOPHAN ,CELL lines ,TUMOR markers ,AMINO acids - Abstract
Simple Summary: Advances in circulating tumor cells (CTCs) research could improve the way we diagnose, treat and monitor epithelial ovarian cancer (EOC) patients. In this study, we investigated the interplay between inflammation-induced systemic catabolic markers and the presence of CTCs and patient outcome, and showed that the presence of CTCs goes hand-in-hand with an increased protein turnover and immune activation. We integrated the information provided by measuring the plasma levels of albumin, tryptophan and its metabolite kynurenine in a combined score for cancer exhaustion (CCES). Our study indicates that not only could the CCES be a useful prognostic biomarker in women with EOC, but also that the interaction between the systemic microenvironment and CTCs is worth investigating in further studies. We investigated the prognostic role of systemic characteristics for cancer exhaustion and the presence of circulating tumor cells (CTCs) in primary epithelial ovarian cancer (EOC) patients. We included 185 patients in this multicenter study with a median follow-up time of 10.25 years. Albumin, c-reactive protein (CRP) and the kynurenine to tryptophan ratio (Kyn/Trp) as well as the CTC-related marker cyclophilin C (PPIC) were obtained before primary therapy and were correlated to the respective clinical and outcome data. The information provided by albumin and Kyn/Trp was integrated in a combined score for cancer exhaustion (CCES). A high CCES characterized by hypoalbuminemia and a high Kyn/Trp was associated with both decreased overall and progression-free survival, independent from other known prognostic factors in a multivariable analysis. The presence of PPIC-positive CTCs was significantly associated with a high CCES, highlighting that the interplay between the systemic microenvironment and CTCs should be considered in "liquid biopsy" biomarker assessment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
213. Mineral oil paraffins in human body fat and milk
- Author
-
Concin, Nicole, Hofstetter, Gerda, Plattner, Barbara, Tomovski, Caroline, Fiselier, Katell, Gerritzen, Kerstin, Fessler, Siegfried, Windbichler, Gudrun, Zeimet, Alain, Ulmer, Hanno, Siegl, Harald, Rieger, Karl, Concin, Hans, and Grob, Koni
- Subjects
- *
ALKANES , *MINERAL oils , *TOXICOLOGY , *MILKFAT , *POISONS , *TOXINS - Abstract
Abstract: Paraffins of mineral oil origin (mineral paraffins) were analyzed in tissue fat collected from 144 volunteers with Caesarean sections as well as in milk fat from days 4 and 20 after birth of the same women living in Austria. In the tissue samples, the composition of the mineral paraffins was largely identical and consisted of an unresolved mixture of iso- and cycloalkanes, in gas chromatographic retention times ranging from n-C17 to n-C32 and centered at n-C23/C24. Since the mineral oil products we are exposed to range from much smaller to much higher molecular mass and may contain prominent n-alkanes, the contaminants in the tissue fat must be a residue from selective uptake, elimination by evaporation and metabolic degradation. Concentrations varied between 15 and 360mg/kg fat, with an average of 60.7mg/kg and a median of 52.5mg/kg. Mineral paraffins might be the largest contaminant of our body, widely amounting to 1g per person and reaching 10g in extreme cases. If food were the main source, exposure data would suggest the mineral paraffins being accumulated over many years or even lifetime. The milk samples of day 4 contained virtually the same mixture of mineral paraffins as the tissue fat at concentrations between 10 and 355mg/kg (average, 44.6mg/kg; median, 30mg/kg). The fats from the day 20 milks contained <5–285mg/kg mineral paraffins (average, 21.7; median, 10mg/kg), whereby almost all elevated concentrations were linked with a modified composition, suggesting a new source, such as the use of breast salves. The contamination of the milk fat with mineral paraffins seems to decrease more rapidly than for other organic contaminants, and the transfer of mineral paraffins to the baby amounts to only around 1% of that in the body of the mother. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
214. Type-Specific Antiviral Antibodies to Genital Human Papillomavirus Types in Mothers and Newborns.
- Author
-
Heim, Kurt, Hudelist, Gernot, Geier, Andrea, Szedenik, Hannes, Christensen, Neil D., Concin, Nicole, Bergant, Anton, Volgger, Birgit, Czerwenka, Klaus, and Höpfl, Reinhard
- Subjects
ANTIVIRAL agents ,VIRAL antibodies ,PAPILLOMAVIRUSES ,MATERNAL-fetal exchange ,SEROLOGY ,IMMUNOGLOBULINS - Abstract
Type-specific antibodies to human papillomaviruses (HPVs) can be detected in most infected adult patients, and they have virus-neutralizing properties. However, there is a dearth of information on the seroprevalence of maternal and neonatal antibodies to HPV capsid antigens. Sera from 104 mothers, their newborns, and 3 twin pregnancies were analyzed by an enzyme-linked immunosorbent assay (ELISA) for the presence of specific IgG, IgM, and IgA antibodies to virus-like particles of HPV-6, -11, -16, -18, and -31. Maternal IgG positivity rates to HPV types 6, 11, 16, 18, and 31 were 23.1%, 2.9%, 8.7%, 5.8%, and 9.6%, respectively. Neonatal rates did not differ significantly, and individual IgG ELISA values of mothers and their infants and all paired twins showed a very high correlation. In contrast, nearly all IgM and IgA individual values in newborns were designated negative, whereas mothers' positivity rates ranged as high as 19.2%. Infants showed no HPV-related lesions at birth or at 4-year follow-up. Seven of 8 tested children lost IgG HPV antibodies in a follow-up examination. Similar anti-HPV IgG seropositivity in mothers and newborns and a lack of neonatal IgA and IgM together with twin and follow-up results indicate that neonatal IgG is not a sign of intrauterine HPV infection but, rather, maternofetal antibody transmission. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
215. ESGO contribution to the WHO initiative on elimination of cervical cancer.
- Author
-
Gultekin, Murat, Morice, Philippe, Concin, Nicole, and Querleu, Denis
- Subjects
CERVICAL cancer ,RADIOTHERAPY ,PAPILLOMAVIRUSES ,META-analysis - Published
- 2020
- Full Text
- View/download PDF
216. The Predictive Value of the Fibrinogen–Albumin-Ratio Index on Surgical Outcomes in Patients with Advanced High-Grade Serous Ovarian Cancer.
- Author
-
Postl, Magdalena, Danisch, Melina, Schrott, Fridolin, Kofler, Paul, Petrov, Patrik, Aust, Stefanie, Concin, Nicole, Polterauer, Stephan, and Bartl, Thomas
- Subjects
- *
PREDICTIVE tests , *RECEIVER operating characteristic curves , *ASCITES , *OVARIAN tumors , *LOGISTIC regression analysis , *PREOPERATIVE care , *CYTOREDUCTIVE surgery , *RETROSPECTIVE studies , *MULTIVARIATE analysis , *CANCER patients , *ODDS ratio , *FIBRINOGEN , *ALBUMINS , *TUMOR classification , *TUMOR antigens , *CONFIDENCE intervals , *BIOMARKERS , *PLATINUM ,TUMOR surgery - Abstract
Simple Summary: The optimal selection of patients with advanced high-grade serous ovarian cancer (HGSOC) who are likely to benefit from upfront cytoreductive surgery remains challenging. With the results of the TRUST trial, the fifth randomized phase III trial comparing oncologic outcomes of primary versus interval cytoreductive surgery, expected to be presented soon, there is a high unmet clinical need to define novel biomarkers to optimize pretherapeutic patient assessment and allow for more personalized clinical decision making. Building on the growing evidence of the predictive and prognostic value of fibrinogen in various solid cancers, this study is the first to observe an independent association between the "Fibrinogen–Albumin-Ratio Index" (FARI) and surgical outcomes in patients with advanced HGSOC undergoing primary cytoreductive surgery. Given that the FARI seems to act as a surrogate for intra-abdominal tumor load, the further clinical validation of this cost-effective and readily available biomarker appears promising. Background/Objectives: The present study evaluates predictive implications of the pretherapeutic Fibrinogen–Albumin-Ratio Index (FARI) in high-grade serous ovarian cancer (HGSOC) patients undergoing primary cytoreductive surgery. Methods: This retrospective study included 161 patients with HGSOC International Federation of Gynecology and Obstetrics (FIGO) stage ≥ IIb, who underwent primary cytoreductive surgery followed by platinum-based chemotherapy. Associations between the FARI and complete tumor resection status were described by receiver operating characteristics, and binary logistic regression models were fitted. Results: Higher preoperative FARI values correlated with higher ascites volumes (r = 0.371, p < 0.001), and higher CA125 levels (r = 0.271, p = 0.001). A high FARI cut at its median (≥11.06) was associated with lower rates of complete tumor resection (OR 3.13, 95% CI [1.63–6.05], p = 0.001), and retrained its predictive value in a multivariable model independent of ascites volumes, CA125 levels, FIGO stage, and Charlson Comorbidity Index (CCI). Conclusions: The FARI appears to act as a surrogate for higher intra-abdominal tumor load. After clinical validation, FARI could serve as a readily available serologic biomarker to complement preoperative patient assessment, helping to identify patients who are likely to achieve complete tumor resection during primary cytoreductive surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
217. Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?
- Author
-
Onoprienko, Arina, Bartl, Thomas, Grimm, Christoph, Concin, Nicole, and Polterauer, Stephan
- Subjects
- *
MITOGEN-activated protein kinases , *CANCER relapse , *DRUG resistance in cancer cells , *DIFFUSION of innovations , *OVARIAN tumors , *RARE diseases , *ANTINEOPLASTIC agents , *CYTOREDUCTIVE surgery , *CANCER chemotherapy , *QUALITY of life , *TUMORS , *LETROZOLE - Abstract
Simple Summary: Low-grade serous ovarian cancer is a rare and complex subtype that usually develops slowly and predominantly affects younger women. Conventional treatment, which generally involves a combination of primary surgery and chemotherapy, often fails, leading to frequent recurrences. Due to the rarity of this cancer subtype, there are limited clinical data available to guide optimal treatment decisions. However, recent research is focusing on new, promising therapies, including targeted treatments that address specific molecular pathways and hormonal therapies. These emerging options offer hope for improved outcomes by enabling more personalized and effective management. This review aims to address the current treatment challenges and summarize the innovative therapies and their potential to enhance treatment strategies, aiming to provide better management for patients with this uncommon ovarian cancer subtype. Low-grade serous ovarian carcinoma (LGSOC) is a rare subtype of epithelial ovarian cancer, characterized by a unique molecular background and specific clinical behavior. A growing body of molecular data underscores LGSOC as a distinct disease entity; however, clinical evidence on the optimal treatment regimens for LGSOC remains limited due to the low incidence of the disease. Consequently, treatment recommendations for LGSOC are still often derived from findings on the more common high-grade serous ovarian carcinoma (HGSOC) and typically focus on radical cytoreductive surgery and platinum-based chemotherapy. Since LGSOCs typically exhibit only limited responsiveness to platinum-based chemotherapy, the clinical management of advanced and recurrent LGSOCs remains a significant therapeutic challenge and often results in limited treatment options and suboptimal outcomes. Recent advances in molecular profiling and the identification of new, promising targets, such as the mitogen-activated protein kinase (MAPK) pathway, offer hope for improving both the prognosis and health-related quality of life in affected patients. Given the high unmet clinical need to establish new therapeutic standards beyond cytotoxic chemotherapy, this review aims to summarize the most promising molecular targets and emerging targeted agents. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
218. BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer.
- Author
-
Pilyugin, Maxim, Ratajska, Magdalena, Stukan, Maciej, Concin, Nicole, Zeillinger, Robert, and Irminger-Finger, Irmgard
- Subjects
AUTOANTIBODIES ,EARLY detection of cancer ,BLOOD testing ,BREAST cancer ,OVARIAN cancer ,DIAGNOSIS - Abstract
Background: Ovarian cancer (OC) is the most lethal gynaecological cancer. It is often diagnosed at an advanced stage with poor chances for successful treatment. An accurate blood test for the early detection of OC could reduce the mortality of this disease. Methods: Autoantibody reactivity to 20 epitopes of BARD1 and concentration of cancer antigen 125 (CA125) were assessed in 480 serum samples of OC patients and healthy controls. Autoantibody reactivity and CA125 were also tested for 261 plasma samples of OC with or without mutations in BRCA1/2, BARD1, or other predisposing genes, and healthy controls. Lasso statistic regression was applied to measurements to develop an algorithm for discrimination between OC and controls. Findings and interpretation: Measurement of autoantibody binding to a number of BARD1 epitopes combined with CA125 could distinguish OC from healthy controls with high accuracy. This BARD1-CA125 test was more accurate than measurements of BARD1 autoantibody or CA125 alone for all OC stages and menopausal status. A BARD1-CA125-based test is expected to work equally well for average-risk women and high-risk women with hereditary breast and ovarian cancer syndrome (HBOC). Although these results are promising, further data on well-characterised clinical samples shall be used to confirm the potential of the BARD1-CA125 test for ovarian cancer screening. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
219. Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?
- Author
-
Concin, Nicole, Matias-Guiu, Xavier, and Creutzberg, Carien L.
- Subjects
CHEMORADIOTHERAPY ,ENDOMETRIAL cancer ,RENAL cell carcinoma - Published
- 2021
- Full Text
- View/download PDF
220. The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium.
- Author
-
Obermayr, Eva, Reiner, Angelika, Brandt, Burkhard, Braicu, Elena Ioana, Reinthaller, Alexander, Loverix, Liselore, Concin, Nicole, Woelber, Linn, Mahner, Sven, Sehouli, Jalid, Vergote, Ignace, and Zeillinger, Robert
- Subjects
OVARIAN tumors ,STAINS & staining (Microscopy) ,OVARIAN epithelial cancer ,CARCINOGENESIS ,METASTASIS ,CANCER relapse ,FLUORESCENT antibody technique ,CELL lines ,POLYMERASE chain reaction ,PHENOTYPES - Abstract
Simple Summary: In ovarian cancer, often diagnosed at an advanced stage and associated with poor overall survival, with just a third of women surviving five years, the controversial prognostic value of circulating tumor cells (CTCs) is still discussed. Currently CTC diagnostics use either molecular approaches or immunofluorescent staining. Our study shows that, given the heterogeneity and extreme scarcity of CTCs, a multifactorial analysis of CTCs is key. Combining both approaches, qPCR and IF, increased sensitivity and may better capture a treatment-related shift in the molecular phenotypes of CTCs. In addition to a long progression-free interval, the absence of CTCs after treatment was an independent predictor of an excellent outcome in patients who had already survived for five years. Thus, a multifactorial CTC approach can identify patients who have elevated risk of recurrence and death and who may require risk-adapted treatment strategies. Introduction: We previously reported the prognostic impact of circulating tumor cells (CTCs) in a multicenter study on minimal residual disease in primary ovarian cancer. With additional follow-up data, we evaluated the combined CTC approach (CTCs
combo ), in particular for the patients who had survived more than five years. Material and Methods: Blood samples taken at baseline and six months after adjuvant treatment (follow-up) were assessed by quantitative PCR (qPCR) measuring PPIC transcripts and immunofluorescent staining (IF). A positive result with either IF or qPCR was classified as CTCcombo -positive. Further, PPIC was assessed in the primary tumor tissue. Results: The concordance of IF and qPCR was 65% at baseline and 83% after treatment. Results showed that 50.5% of the baseline and 29.5% of the follow-up samples were CTCcombo -positive. CTCscombo after treatment were associated with increased mortality after adjusting for FIGO stage (HR 2.574, 95% CI: 1.227–5.398, p = 0.012), a higher risk of recurrence after adjusting for peritoneal carcinosis (HR 4.068, 95% CI: 1.948–8.498, p < 0.001), and increased mortality after five survived years. Discussion: The two-sided analytical approach revealed CTC subpopulations associated with ovarian cancer progression and may illuminate a potential treatment-related shift in molecular phenotypes. That approach can identify patients who have elevated risk of recurrence and death due to ovarian cancer and who may require risk-adapted treatment strategies. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
221. Clinical Relevance of TAp73 and Np73 Protein Expression in Ovarian Cancer
- Author
-
Hofstetter, Gerda, Berger, Astrid, Chamson, Martina, Müller-Holzner, Elisabeth, Reimer, Daniel, Ulmer, Hanno, Uramoto, Hidetaka, Marth, Christian, Zeimet, Alain G., Zeillinger, Robert, and Concin, Nicole
- Abstract
The p73 gene gives rise to the full-length transactivation competent TAp73 and the N-terminally truncated isoform Np73, which inhibits TAp73 and wild-type p53. The clinical relevance of TAp73 and Np73 protein expression has not yet been evaluated in ovarian cancer. TAp73 and Np73 expression was examined using immunohistochemistry and reverse transcription–polymerase chain reaction in 83 and 64 ovarian cancer specimens, respectively. A yeast-based assay and subsequent sequencing were performed to analyze the p53mutational status. TAp73 and Np73 protein expression was found in 73 of 83 (88) and 48 of 83 (57.8) ovarian cancer samples, respectively. The majority of cases showed immunostaining in both the nucleus and cytoplasm of tumor cells. TAp73 and Np73 protein expression correlated with messenger RNA quantification in 25 of 64 (39.1) and 37 of 64 (57.8) cancer specimens, respectively. TAp73 and Np73 protein expression was not associated with the p53mutational status, clinicopathologic parameters, and prognosis of the examined ovarian cancer cases. Although TAp73 and Np73 protein expression did not possess prognostic significance for ovarian cancer in this study, a potential clinical role of p73 isoforms cannot be definitively excluded due to limitations of immunohistochemistry.
- Published
- 2011
- Full Text
- View/download PDF
222. Comparison of p53Mutational Status with mRNA and Protein Expression in a Panel of 24 Human Breast Carcinoma Cell Lines
- Author
-
Concin, Nicole, Zeillinger, Christa, Tong, Dan, Stimpfl, Margit, König, Margit, Printz, Dieter, Stonek, Felix, Schneeberger, Christian, Hefler, Lukas, Kainz, Christian, Leodolter, Sepp, Haas, Oskar, and Zeillinger, Robert
- Abstract
We analyzed the p53mutational status, mRNA and protein expression in 24 human breast carcinoma cell lines. Following measurement of their DNA content with flow cytometry, we ascertained the copy numbers of the centromere of chromosome 17 (cen17) and p53with fluorescence in situhybridization (FISH). A functional yeast assay (FASAY) was used to screen for inactivating mutations. Positive results were subsequently verified by DNA sequencing. Finally, we assessed the mRNA expression with a competitive reverse transcription-polymerase chain reaction (RT-PCR) assay and the protein expression with immunocytochemical staining, western blot, and quantitative flow cytometry. The DNA content of the cell lines ranged from 0.85 to 2.58. Nine cell lines had concordant copy numbers (between two and four) of p53and cen17, whereas 12 had more, and three less cen17 than p53copies. The FASAY was successful in all but one cell line and revealed the presence of mutated alleles in 16 of them, 13 cell lines expressed only the mutated, and three both the mutated and the wild-type alleles. The mutations were comprised of 11 missense, two nonsense, and three frameshift mutations. Immunocytochemical staining, western blot and quantitative flow cytometry yielded comparable p53 protein expression results. However, both the mRNA and the protein expression levels varied considerably in the different cell lines and no consistent pattern with regard to the respective p53mutational status became evident. The results obtained in these breast carcinoma cell lines indicate that no clear-cut linear relationship exists between the p53mutational status and the extent of its respective mRNA and protein expression. Therefore, direct DNA analyses and functional assays remain the only methods for the reliable detection of p53mutations.
- Published
- 2003
- Full Text
- View/download PDF
223. Erratum zu: 60-jährige Patientin mit fortgeschrittenem Ovarialkarzinom: Vorbereitung auf die Facharztprüfung: Fall 4.
- Author
-
Concin, Nicole and du Bois, Andreas
- Abstract
Copyright of Der Gynäkologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
224. Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESGO) statement.
- Author
-
Querleu, Denis, Cibula, David, Concin, Nicole, Fagotti, Anna, Ferrero, Annamaria, Fotopoulou, Christina, Knapp, Pawel, Kurdiani, Dina, Ledermann, Jonathan A., Mirza, Mansoor Raza, Morice, Philppe, Ponce, Jordi, Van der Steen-Banasik, Elzbieta, Taskiran, Cagatay, Wimberger, Pauline, Zalewski, Kamil, and Sessa, Cristiana
- Abstract
The article reports on a statement issued by the European Society of Gynaecological Oncology (ESGO) Scientific Committee and Council about the ESGO recommendation concerning the validity of the approach for radical surgery for cervical cancer.
- Published
- 2020
- Full Text
- View/download PDF
225. Clear cell carcinoma of the endometrium.
- Author
-
Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Y.L., Morice, Philippe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M., Takano, Masashi, Provencher, Diane, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, and Candido dos Reis, Francisco J.
- Subjects
- *
RENAL cell carcinoma , *UTERINE tumors , *IMMUNE checkpoint inhibitors , *ENDOMETRIAL cancer , *ENDOMETRIUM , *PROTEIN-tyrosine kinase inhibitors , *CANCER patients - Abstract
Clear cell endometrial carcinoma represents an uncommon and poorly understood entity. Data from molecular/genomic profiling highlighted the importance of various signatures in assessing the prognosis of endometrial cancer according to four classes of risk (POLE mutated, MMRd, NSMP, and p53 abnormal). Unfortunately, data specific to clear cell histological subtype endometrial cancer are lacking. More recently, data has emerged to suggest that most of the patients (more than 80%) with clear cell endometrial carcinoma are characterized by p53 abnormality or NSMP type. This classification has important therapeutic implications. Although it is an uncommon entity, clear cell endometrial cancer patients with POLE mutation seem characterized by a good prognosis. Chemotherapy is effective in patients with NSMP (especially in stage III and IV) and patients with p53 abnormal disease (all stages). While, preliminary data suggested that patients with MMRd are less likely to benefit from chemotherapy. The latter group appears to benefit much more from immune checkpoint inhibitors: recent data from clinical trials on pembrolizumab plus lenvatinib and nivolumab plus cabozantinib supported that immunotherapy plus tyrosine kinase inhibitors (TKI) would be the most appropriate treatment for recurrent non-endometrioid endometrial cancer (including clear cell carcinoma) after the failure of platinum-based chemotherapy. Moreover, ongoing clinical trials testing the anti-tumor activity of innovative products will clarify the better strategies for advanced/recurrent clear cell endometrial carcinoma. Further prospective evidence is urgently needed to better characterize clear cell endometrial carcinoma. • Clear cell endometrial cancer represents uncommon uterine tumor. • Multi-modal treatment should be considered in patient with clear cell endometrial cancer. • Immunotherapy might play a role in patients with MMRd clear cell endometrial cancer. • ATr , PIK3CA , DDR , and HER2 might be potential targets in clear cell endometrial cancer [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
226. 2023 FIGO staging system for endometrial cancer: The evolution of the revolution.
- Author
-
Gaffney, David, Matias-Guiu, Xavier, Mutch, David, Scambia, Giovanni, Creutzberg, Carien, Fotopoulou, Christina, Berek, Jonathan S., and Concin, Nicole
- Subjects
- *
ENDOMETRIAL cancer , *HISTORY of biology , *PROGNOSIS , *NATURAL history , *TUMOR classification - Abstract
Embracing the complex and diverse nature of the heterogenous group of malignancies that are included under the umbrella of "endometrial cancer" (EC) to better align prognosis with treatment recommendations, requires a more comprehensive staging system. Our goal at the development of the new FIGO staging was to provide 1) high accuracy in the predictive prognosis for a patient with EC, which is the genuine purpose of a staging system, and 2) identification of distinct treatment relevant subgroups. Since the publication of the 2009 staging system by the International Federation of Gynecology and Obstetrics (FIGO) 14 years ago (1, 2), our understanding of the biology and natural history of EC has undergone a radical transformation. The TGCA results in 2013 (3), and the many validation reports published since then (4–9), have taught us that "EC" is composed of at least four distinct molecularly defined diseases. Strong histopathologic markers reflecting tumor biology such as lymph vascular space invasion (LVSI) were identified. Importantly, anatomical borders were shown to lose their prognostic relevance for EC patients in the presence of dominant tumor biology-markers such as molecular subtypes/LVSI (10, 11). This emphasizes the integration of these novel markers into a prognostic staging system that aims to be relevant to patients. The 2023 FIGO staging system for EC harmonizes and integrates old and new knowledge on anatomic, histopathologic, and molecular features (12). It requires a change in our perception of a staging system, from a traditional purely anatomical borders-based system to an integrated staging system integrating anatomical borders and tumor biology as pivotal prognostic factors for EC patients while providing important information for treatment decision making. Therefore, the 2023 FIGO staging system demonstrates the logical next step in the evolution of the revolution in a patient-centric staging approach. Below, we elucidate the rationale for the FIGO 2023 endometrial cancer staging system. • 2023 FIGO staging system integrates old and new knowledge on anatomic, histopathologic, and (optional) molecular features. • 2023 FIGO is superior to 2009 FIGO in the prediction of survival, confirmed by to do date 5 validation studies. • 2023 FIGO adds prognostic granularity and identifies treatment-relevant subgroups of EC patients. • 2023 FIGO reinforces molecular testing to EC patients leveraging a strong demand for global access. • FIGO 2023 system will spur worldwide adoption of molecular classification so more tailored therapy will be adopted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
227. Fetal weight estimation at term - ultrasound versus clinical examination with Leopold's manoeuvres: a prospective blinded observational study.
- Author
-
Preyer, Oliver, Husslein, Heinrich, Concin, Nicole, Ridder, Anna, Musielak, Maciej, Pfeifer, Christian, Oberaigner, Willi, and Husslein, Peter
- Subjects
OBSTETRICS ,BODY mass index ,WEIGHT gain in pregnancy ,PRENATAL care ,MAGNETIC resonance imaging - Abstract
Background: Fetal weight estimation is of key importance in the decision-making process for obstetric planning and management. The literature is inconsistent on the accuracy of measurements with either ultrasound or clinical examination, known as Leopold's manoeuvres, shortly before term. Maternal BMI is a confounding factor because it is associated with both the fetal weight and the accuracy of fetal weight estimation. The aim of our study was to compare the accuracy of fetal weight estimation performed with ultrasound and with clinical examination with respect to BMI.Methods: In this prospective blinded observational study we investigated the accuracy of clinical examination as compared to ultrasound measurement in fetal weight estimation, taking the actual birth weight as the gold standard. In a cohort of all consecutive patients who presented in our department from January 2016 to May 2017 to register for delivery at ≥37 weeks, examination was done by ultrasound and Leopold's manoeuvres to estimate fetal weight. All examiners (midwives and physicians) had about the same level of professional experience. The primary aim was to compare overall absolute error, overall absolute percent error, absolute percent error > 10% and absolute percent error > 20% for weight estimation by ultrasound and by means of Leopold's manoeuvres versus the actual birth weight as the given gold standard, namely separately for normal weight and for overweight pregnant women.Results: Five hundred forty-three patients were included in the data analysis. The accuracy of fetal weight estimation was significantly better with ultrasound than with Leopold's manoeuvres in all absolute error calculations made in overweight pregnant women. For all error calculations performed in normal weight pregnant women, no statistically significant difference was seen in the accuracy of fetal weight estimation between ultrasound and Leopold's manoeuvres.Conclusions: Data from our prospective blinded observational study show a significantly better accuracy of ultrasound for fetal weight estimation in overweight pregnant women only as compared to Leopold's manoeuvres with a significant difference in absolute error. We did not observe significantly better accuracy of ultrasound as compared to Leopold's manoeuvres in normal weight women. Further research is needed to analyse the situation in normal weight women. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
228. Uterine serous carcinoma.
- Author
-
Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Y.L., Morice, Philippe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Nout, Remi A., Lorusso, Domenica, Vaughan, Michelle M., Bini, Marta, Takano, Masashi, Provencher, Diane, Indini, Alice, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, and Kim, Se Ik
- Subjects
- *
ENDOMETRIAL tumors , *ENDOMETRIAL cancer , *SURVIVAL rate , *GYNECOLOGIC oncology , *IMMUNE checkpoint inhibitors , *GYNECOLOGIC cancer - Abstract
Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related deaths. Patients with serous endometrial cancer are often diagnosed at earlier disease stage, but remain at higher risk of recurrence and poorer prognosis when compared stage-for-stage with endometrioid subtype endometrial cancer. Serous endometrial cancers are characterized by marked nuclear atypia and abnormal p53 staining in immunohistochemistry. The mainstay of treatment for newly diagnosed serous endometrial cancer includes a multi-modal therapy with surgery, chemotherapy and/or radiotherapy. Unfortunately, despite these efforts, survival outcomes still remain poor. Recently, The Cancer Genome Atlas (TCGA) Research Network classified all endometrial cancer types into four categories, of which, serous endometrial cancer mostly is found within the "copy number high" group. This group is characterized by the increased cell cycle deregulation (e.g., CCNE1 , MYC, PPP2R1A , PIKCA, ERBB2 and CDKN2A) and TP53 mutations (90%). To date, the combination of pembrolizumab and lenvatinib is an effective treatment modality in second-line therapy, with a response rate of 50% in advanced/recurrent serous endometrial cancer. Owing to the unfavorable outcomes of serous endometrial cancer, clinical trials are a priority. At present, ongoing studies are testing novel combinations of various targeted and immunotherapeutic agents in newly diagnosed and advanced/recurrent endometrial cancer - an important strategy for serous endometrial cancer, whereby tumors are usually p53+ and pMMR, making response to PD-1 inhibitor monotherapy unlikely. Here, the rare tumor working group (including members from the European Society of Gynecologic Oncology (ESGO), Gynecologic Cancer Intergroup (GCIG), and Japanese Gynecologic Oncology Group (JGOG)), performed a narrative review reporting on the current landscape of serous endometrial cancer and focusing on standard and emerging therapeutic options for patients affected by this difficult disease. • Uterine serous carcinoma (USC) is a rare and aggressive variant of endometrial cancer. • USCs are generally mismatch repair proficient and have extensive copy number alterations. • Multi-modal treatment including surgery, chemotherapy and/or radiotherapy should be considered in the majority patient with USC. • Novel combinations of immune checkpoint inhibitors with targeted therapies are under evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
229. Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells
- Author
-
Kramer, Daniela, Stark, Nadine, Schulz-Heddergott, Ramona, Erytch, Norman, Edmunds, Shelley, Roßmann, Laura, Bastians, Holger, Concin, Nicole, Moll, Ute, and Dobbelstein, Matthias
- Abstract
Since publication of this article, the authors reported that the online version is missing the links to most of the Supplementary data, specifically, Supplementary Figures S1–S9; Supplementary Table S1; all legends to Supplementary Material.
- Published
- 2019
- Full Text
- View/download PDF
230. Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study.
- Author
-
Imterat, Majdi, Gebers, Gudrun, Heitz, Florian, Schneider, Stephanie, Ehmann, Sarah, Welz, Julia, du Bois, Andreas, Traut, Alexander, Walz, Martin K., Concin, Nicole, Harter, Philipp, and Ataseven, Beyhan
- Subjects
- *
OSTOMATES , *QUALITY of life , *LONGITUDINAL method , *DISEASE relapse , *CARCINOMA , *OSTEOCHONDROSIS - Abstract
Bowel dysfunction is frequently reported in patients with ovarian carcinoma (OC). Our aim was to evaluate the incidence of low anterior resection syndrome (LARS) like symptoms in patients with primary OC and its impact on quality of life (QoL). A prospective longitudinal observational cohort study was performed, including patients with newly diagnosed OC treated by primary or interval surgery with residual tumor <1 cm, from 2018 until 2021. Patients with a stoma or recurrence of disease were excluded. Intestinal dysfunction was assessed using the validated LARS score questionnaire pre- and postoperatively. There are 3 subgroups based on the results: no, minor, or major LARS. The impact on QoL was evaluated by an additional question to demonstrate the severity of patient's life impairment. The questionnaire was answered by 78 patients pre- and post-operatively. LARS like symptoms were reported preoperatively in 34.6% (24.4% minor/10.2% major) and significantly increased postoperatively to 47.4% (28.2% minor/19.2% major; p = 0.011). Moderate to severe impairment of QoL correlated with LARS scores pre- (80%) and post-operatively (90%). Patients with two bowel anastomoses (mean score 18.6 pre- and 24.9 post-operatively, p = 0.041) showed a significant increase of the questionnaire score. Major LARS like symptoms appear in 10% of OC patients preoperatively and significantly increase to almost two-fold postoperatively. Multiple bowel anastomoses had a significant risk for higher postoperative LARS score. QoL impairment correlates linearly with LARS positive scoring, independent on the timing of the complaints. • Preoperative Major LARS like symptoms were non-negligible in frequency and observed in about 10% of ovarian carcinoma. • It increased to almost two-fold postoperatively (19.2%), independent of undergoing a low anterior resection. • QoL impairment correlated strongly with LARS scoring, regardless of the evaluation timepoint (pre- or postoperatively). • Multiple bowel anastomoses were the only identified risk factor for a LARS scoring increase. • A preoperative detailed patient counselling about a higher incidence of LARS in these cases is necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
231. FIGO staging of endometrial cancer: 2023.
- Author
-
Berek, Jonathan S., Matias-Guiu, Xavier, Creutzberg, Carien, Fotopoulou, Christina, Gaffney, David, Kehoe, Sean, Lindemann, Kristina, Mutch, David, and Concin, Nicole
- Subjects
- *
MICROMETASTASIS , *ENDOMETRIAL cancer , *TUMOR classification , *LYMPHATIC metastasis , *CANCER patients - Abstract
Introduction: Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies. Methods: The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system. Results: Based on the existing evidence, the substages were defined as follows: S tage I (IA1): non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion. S tage II (IIA): non-aggressive histological types that infiltrate the cervical stroma; (IIB) nonaggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion. S tage III (IIIA): differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis. S tage IV (IVA): locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis. The performance of complete molecular classification ( POLEmut, MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of "m" for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or POLEmut status in Stages I and II, this results in upstaging or downstaging of the disease (IICmp53abn or IAmPOLEmut). Summary: The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
232. Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients.
- Author
-
Imterat, Majdi, Harter, Philipp, Rhiem, Kerstin, Heitz, Florian, Schneider, Stephanie, Concin, Nicole, Moubarak, Malak, Welz, Julia, Vrentas, Vasileios, Traut, Alexander, Hahnen, Eric, Schmutzler, Rita, du Bois, Andreas, and Ataseven, Beyhan
- Subjects
- *
GENETIC mutation , *OVARIAN tumors , *CONFIDENCE intervals , *BRCA genes , *MULTIVARIATE analysis , *RETROSPECTIVE studies , *CANCER patients , *DESCRIPTIVE statistics , *PROGRESSION-free survival , *LONGITUDINAL method , *OVERALL survival - Abstract
Simple Summary: The availability of multiple gene panel testing allows us to identify germline pathogenic variants of validated cancer genes. We evaluated the prevalence and clinical/prognostic impact of deleterious germline mutations in OC patients. Germline panel testing should be performed for all patients with ovarian cancer. Better prognosis was found for germline mutated ovarian cancer patients. Endometrioid and clear cell histology subtypes show more deleterious mutations in other genes. Data on deleterious variants in genes other than BRCA1/2 remain limited. A retrospective cohort study was performed, including primary OC cases with TruRisk® germline gene panel testing between 2011 and 2020. Patients with testing after relapse were excluded. The cohort was divided into three groups: (A) no mutations, (B) deleterious BRCA1/2 mutations, and (C) deleterious mutations in other genes. A total of 702 patients met the inclusion criteria. Of these 17.4% (n = 122) showed BRCA1/2 mutations and a further 6.0% (n = 42) in other genes. Three-year overall survival (OS) of the entire cohort was significantly longer in patients with germline mutations (85%/82.8% for cohort B/C vs. 70.2% for cohort A, p < 0.001) and 3-year progression-free survival (PFS) only for cohort B (58.1% vs. 36.9%/41.6% in cohort A/C, p = 0.002). In multivariate analysis for the subgroup of advanced-stages of high-grade serous OC, both cohorts B/C were found to be independent factors for significantly better outcome, cohort C for OS (HR 0.46; 95% CI 0.25–0.84), and cohort B for both OS and PFS (HR 0.40; 95% CI 0.27–0.61 and HR 0.49; 95% CI 0.37–0.66, respectively). Germline mutations were detected in a quarter of OC patients, and a quarter of those in genes other than BRCA1/2. Germline mutations demonstrate in our cohort a prognostic factor and predict better prognosis for OC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
233. Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer.
- Author
-
Heitz, Florian, Ataseven, Beyhan, Staniczok, Claudia, Denkert, Carsten, Rhiem, Kerstin, Hahnen, Eric, Heikaus, Sebastian, Moubarak, Malak, Welz, Julia, Dagres, Timoleon, Vrentas, Vasilios, Bommert, Mareike, Schneider, Stephanie, Concin, Nicole, and Harter, Philipp
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *CLINICAL pathology , *GENETIC mutation , *OVARIAN tumors , *CARBOPLATIN , *SEQUENCE analysis , *BRCA genes , *INDUSTRIAL property , *DECISION making , *DESCRIPTIVE statistics , *TISSUES , *PACLITAXEL , *BEVACIZUMAB , *COLLECTION & preservation of biological specimens , *ENZYME inhibitors - Abstract
Simple Summary: Testing for a homologous recombination deficiency (HRD) in primary high-grade ovarian cancer is crucial for recommending the appropriate therapy. Patients with a BRCA germline mutation are defined as harboring an HRD deficiency. However, there is a group of approximately 20% of patients without a BRCA mutation which harbor an HRD deficiency based on tumor genomic analyses. In the current research, we wanted to share the experience of a high-volume tertiary cancer center with implementing central HRD testing—in another institution—to reduce doubts about logistic issues and to the highlight critical aspects that hinder HRD testing. We showed that the results of HRD testing became available in a timely manner for the therapy decision. However, it was important to obtain as much tumor tissue as possible during the first diagnosis—before any other intervention—as the tumor quantity and quality were critical for HRD testing. Additional BRCA germline testing further reduced the failures of HRD testing and should additionally be routinely conducted. The chemotherapy backbone for patients with high-grade advanced epithelial ovarian cancer (HG-AOC) is carboplatin and paclitaxel followed by a maintenance therapy either with bevacizumab, with a PARP inhibitor, or with a combination of both, which is defined by the presence of a homologous recombination deficiency (HRD) and by the BRCA1/2 status. This study included patients with a primary diagnosis of HG-AOC treated between December 2019 and December 2021. The HRD status was measured using the Myriad myChoice® test on all the patients with an indication for tumor HRD testing. Germline testing was conducted on all the patients using the TruRisk® panel as recommended by the national guidelines. HRD testing was requested for 190 patients, and, for 163 patients (85.8%), an HRD test result was available. An HRD test result could not be reported in 27 patients due to an insufficient tumor yield. The median time that it took to receive the HRD test results was 37 days (range of 8–97). In total, an HRD was present in 44.7% (73/163) of the patients based on a GIS ≥ 42 in 42.9% of the patients and based on a tumor BRCA1/2 mutation in 3 cases (all with a GIS < 42). The germline testing results were available for 148 patients, and, in 18 patients (12.2%), a deleterious germline mutation was detected. Of the 27 patients without sufficient HRD testing, BRCA1/2 germline testing results were available for 19 patients (70.4%), and a deleterious germline mutation was detected in 2 patients (7.4%). The implementation of HRD testing is feasible, and the results become available for treatment decisions in a timely manner for most patients. The prerequisite for HRD testing with the Myriad myChoice® test is a sufficient amount of tumor tissue. The cotesting of HRD and BRCA1/2 germline testing should be aimed for in order to enable optimal and timely treatment decisions on maintenance therapy as well as to test patients on whom the HRD test will not be evaluable. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
234. Response: Analysis of adjuvant therapy in early staged endometrioid endometrial cancer—FIGO 2023 classification.
- Author
-
Mutch, David, Gaffney, David, Matias‐Guiu, Xavier, Fotopoulou, Christina, Concin, Nicole, and Berek, Jonathan S.
- Subjects
- *
ENDOMETRIAL cancer , *GAIN-of-function mutations , *ENDOMETRIAL tumors - Abstract
This document is a response to a comment regarding the FIGO 2023 endometrial cancer staging. The authors acknowledge the importance of molecular evaluation in cancer staging and explain that p53 status is included as a feature in the staging of endometrial cancers. They address concerns about whether an isolated p53 mutation automatically confers a worse prognosis and explain that while it may not always be the case, most often p53 mutations are a prognostic discriminator. The authors emphasize that treatment decisions should be made by the treating physician based on various factors, and that the FIGO staging system is designed to help categorize patients and guide treatment decisions. They appreciate the comment and state that future iterations of the staging system will take it into consideration. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
235. Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer.
- Author
-
Vanderstichele, Adriaan, Loverix, Liselore, Busschaert, Pieter, Van Nieuwenhuysen, Els, Han, Sileny N., Concin, Nicole, Callewaert, Tiene, Olbrecht, Siel, Salihi, Rawand, Berteloot, Patrick, Neven, Patrick, Lambrechts, Diether, Van Gorp, Toon, and Vergote, Ignace
- Subjects
- *
OVARIAN cancer , *OLAPARIB , *PHYSICIANS , *PROGRESSION-free survival , *CANCER chemotherapy - Abstract
Comparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC). Patients with measurable disease and ≥ 1 prior line of chemotherapy (CT) were randomized 2:1 to OLA (300 mg tablets, BID) or physician's choice CT.: for PSOC: Carboplatin-Pegylated-Liposomal-Doxorubicin (PLD) or Carboplatin-Gemcitabine; for PROC: PLD, Topotecan, Paclitaxel or Gemcitabine. 160 patients (60 with PSOC and 100 with PROC) were randomized 2:1 to OLA (n = 107) or CT (n = 53). Baseline characteristics were similar between both arms. Overall objective response rate (ORR) for OLA and CT were similar (24.3% (26/107) and 28.3% (15/53), respectively). Clinical benefit rate (≥ 12 weeks) was similar with 54.2% (58/107) and 56.6% (30/53), respectively. In PSOC, ORR was 35.0% (14/40) and 65.0% (13/20) for OLA and CT (p = 0.053); in PROC, ORR was 17.9% (12/67) and 6.1% (2/33) for OLA and CT (p = 0.134). ORR in heavily pretreated PROC (>4 prior lines) was 22.9% (8/35) with OLA versus 0% (0/14) for CT. ORR of 35.7% (5/14) and 13.2% (7/53) was observed in BRCA-mutated and -wildtype PROC cases, respectively. Median PFS in PROC was not significantly different with 2.9 months (95% CI 2.8–5.1 in the OLA group versus 3.8 months (95% CI 3.0–6.4) in the CT group (hazard ratio [HR] 1.11 [95% CI 0.72–1.78]; log-rank p = 0.600). OLA monotherapy showed overall an equal response rate in relapsed ovarian cancer compared with CT. In PROC, ORR and TFST tended to be higher with OLA than with CT. In heavily pretreated patients (four lines or more) with PROC disease, OLA treatment seemed to be more effective than CT. • Phase II randomized study of olaparib monotherapy versus chemotherapy in recurrent ovarian cancer • Objective response rate was overall similar in the total study (n = 160) for olaparib and chemotherapy • In platinum-sensitive disease the response rate was numerically higher with chemotherapy • Progression free survival, clinical benefit rate and overall survival were overall not significantly different. • In platinum-resistant ovarian cancer with ≥4 prior lines, olaparib seemed to be more effective than chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
236. Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study.
- Author
-
Watrowski, Rafał, Obermayr, Eva, Wallisch, Christine, Aust, Stefanie, Concin, Nicole, Braicu, Elena Ioana, Van Gorp, Toon, Hasenburg, Annette, Sehouli, Jalid, Vergote, Ignace, and Zeillinger, Robert
- Subjects
- *
BIOMARKERS , *RESEARCH , *OVARIAN tumors , *CONFIDENCE intervals , *DESCRIPTIVE statistics , *PREDICTION models , *ADNEXAL diseases , *TUMOR markers , *DATA analysis software , *LOGISTIC regression analysis , *ALGORITHMS - Abstract
Simple Summary: Ovarian cancer (OC) is the deadliest genital tumor in women. In this multicenter study, we developed three new diagnostic models based on serum proteins and patient age. All models were then validated using data from centers other than those used for the model development. We also compared the performance of these models with common singular markers (CA125, HE4) and algorithms (ROMA-50 and the Copenhagen Index). We used modern technology (Luminex®, Austin, TX, USA) that enables the simultaneous determination of several biomarkers in a small amount of blood. A combination of patient age with four to six markers performed best: CA125, osteopontin, prolactin, macrophage migration inhibitory factor, and, eventually, HE4 and leptin. Our models were better than the ROMA-50 index but did not outperform the Copenhagen Index. In postmenopausal patients, all the newly developed models performed excellently. Unfortunately, none of the models tested improved the diagnosis in premenopausal patients and those missed due to normal CA125 levels. Ovarian cancer (OC) is the most lethal genital malignancy in women. We aimed to develop and validate new proteomic-based models for non-invasive diagnosis of OC. We also compared them to the modified Risk of Ovarian Malignancy Algorithm (ROMA-50), the Copenhagen Index (CPH-I) and our earlier Proteomic Model 2017. Biomarkers were assessed using bead-based multiplex technology (Luminex®) in 356 women (250 with malignant and 106 with benign ovarian tumors) from five European centers. The training cohort included 279 women from three centers, and the validation cohort 77 women from two other centers. Of six previously studied serum proteins (CA125, HE4, osteopontin [OPN], prolactin, leptin, and macrophage migration inhibitory factor [MIF]), four contributed significantly to the Proteomic Model 2021 (CA125, OPN, prolactin, MIF), while leptin and HE4 were omitted by the algorithm. The Proteomic Model 2021 revealed a c-index of 0.98 (95% CI 0.96, 0.99) in the training cohort; however, in the validation cohort it only achieved a c-index of 0.82 (95% CI 0.72, 0.91). Adding patient age to the Proteomic Model 2021 constituted the Combined Model 2021, with a c-index of 0.99 (95% CI 0.97, 1) in the training cohort and a c-index of 0.86 (95% CI 0.78, 0.95) in the validation cohort. The Full Combined Model 2021 (all six proteins with age) yielded a c-index of 0.98 (95% CI 0.97, 0.99) in the training cohort and a c-index of 0.89 (95% CI 0.81, 0.97) in the validation cohort. The validation of our previous Proteomic Model 2017, as well as the ROMA-50 and CPH-I revealed a c-index of 0.9 (95% CI 0.82, 0.97), 0.54 (95% CI 0.38, 0.69) and 0.92 (95% CI 0.85, 0.98), respectively. In postmenopausal women, the three newly developed models all achieved a specificity of 1.00, a positive predictive value (PPV) of 1.00, and a sensitivity of >0.9. Performance in women under 50 years of age (c-index below 0.6) or with normal CA125 (c-index close to 0.5) was poor. CA125 and OPN had the best discriminating power as single markers. In summary, the CPH-I, the two combined 2021 Models, and the Proteomic Model 2017 showed satisfactory diagnostic accuracies, with no clear superiority of either model. Notably, although combining values of only four proteins with age, the Combined Model 2021 performed comparably to the Full Combined Model 2021. The models confirmed their exceptional diagnostic performance in women aged ≥50. All models outperformed the ROMA-50. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
237. ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers.
- Author
-
Sessa, Cristiana, Schneider, Dominik T, Planchamp, François, Baust, Katja, Braicu, Elena Ioana, Concin, Nicole, Godzinski, Jan, McCluggage, W Glenn, Orbach, Daniel, Pautier, Patricia, Peccatori, Fedro A, Morice, Philippe, and Calaminus, Gabriele
- Subjects
- *
GERM cell tumors , *OVARIAN tumors , *MEDICAL protocols , *ONCOLOGY , *DISEASE management - Abstract
The European Society of Gynaecological Oncology and the European Society for Paediatric Oncology jointly developed clinically relevant and evidence-based guidelines for the management of adolescents and young adults aged 15 to 25 years with non-epithelial ovarian cancers, including malignant ovarian germ cell tumours, sex cord-stromal tumours, and small cell carcinoma of the ovary of hypercalcaemic type. The developmental process of these guidelines is based on a systematic literature review and critical appraisal process involving an international multidisciplinary developmental group consisting of experts from relevant disciplines (paediatric oncology, paediatric surgery, medical oncology, pathology, psycho-oncology, gynaecological oncology, and reproductive endocrinology). Given the specific and often complex issues involved in treating this group of patients, fertility sparing surgery and decrease of acute and long-term toxicities from treatment were important criteria for guidelines definition. Prior to publication, the guidelines were reviewed by 54 independent international practitioners in cancer care delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
238. Lymph node staging in grade 1–2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
- Author
-
Bizzarri, Nicolò, Imterat, Majdi, Fruscio, Robert, Giannarelli, Diana, Perrone, Anna Myriam, Mancari, Rosanna, Traut, Alexander, Rosati, Andrea, du Bois, Andreas, Ferrari, Debora, De Iaco, Pierandrea, Ergasti, Raffaella, Ataseven, Beyhan, Bianchi, Tommaso, Di Stanislao, Marco, Perri, Maria Teresa, Heitz, Florian, Concin, Nicole, Fanfani, Francesco, and Vizza, Enrico
- Subjects
- *
RESEARCH , *OVARIAN tumors , *LYMPHADENECTOMY , *SCIENTIFIC observation , *CONFIDENCE intervals , *RETROSPECTIVE studies , *ACQUISITION of data , *METASTASIS , *LYMPH nodes , *TUMOR classification , *CANCER patients , *MEDICAL records , *SURVIVAL analysis (Biometry) , *KAPLAN-Meier estimator , *DESCRIPTIVE statistics , *PROGRESSION-free survival , *TUMOR grading , *LONGITUDINAL method , *OVERALL survival , *PROPORTIONAL hazards models - Abstract
The aim of this study was to assess the disease-free survival (DFS) and overall survival (OS) of patients with grade 1–2 endometrioid ovarian carcinoma apparently confined to the ovary, according to surgical staging. Multicenter, retrospective, observational cohort study. Patients with endometrioid ovarian carcinoma, surgical procedure performed between May 1985 and December 2019, stage pT1 N0/N1/Nx, grade 1–2 were included. Patients were stratified according to lymphadenectomy (defined as removal of any lymph node versus no lymph node assessment), and subgroup analyses according to tumor grade were performed. Kaplan-Meier curves and cox regression analyses were used to perform survival analyses. 298 patients were included. 199 (66.8 %) patients underwent lymph node assessment. Of these, 166 (83.4 %) had unilateral/bilateral pelvic and para-aortic/caval lymphadenectomy. Eleven (5.5 %) patients of those who underwent lymph node assessment showed pathologic metastatic lymph nodes (FIGO stage IIIA1). Twenty-seven patients (9.1 %) had synchronous endometrioid endometrial cancer. After a median follow up of 45 months (95 %CI:37.5–52.5), 5-year DFS and OS of the entire cohort were 89.8 % and 96.2 %, respectively. Age ≤ 51 years (HR=0.24, 95 %CI:0.06–0.91; p = 0.036) and performance of lymphadenectomy (HR=0.25, 95 %CI: 0.07–0.82; p = 0.022) represented independent protective factors toward risk of death. Patients undergoing lymphadenectomy had better 5-year DFS and OS compared to those not receiving lymphadenectomy, 92.0 % versus 85.6 % (p = 0.016) and 97.7 % versus 92.8 % (p = 0.013), respectively. This result was confirmed after exclusion of node-positive patients. When stratifying according to tumor grade (node-positive excluded), patients with grade 2 who underwent lymphadenectomy had better 5-year DFS and OS than those without lymphadenectomy (93.0 % versus 83.1 %, p = 0.040 % and 96.5 % versus 90.6 %, p = 0.037, respectively). Staging lymphadenectomy in grade 2 endometrioid ovarian carcinoma patients was associated with improved DFS and OS. Grade 1 and grade 2 might be considered as two different entities, which could benefit from different approach in terms of surgical staging. Prospective studies, including molecular profiles are needed to confirm the survival drivers in this rare setting. • Prognostic role of lymphadenectomy in G1-2 endometrioid ovarian cancer is unclear. • 5.5 % patients showed pathologic metastatic lymph nodes. • 81.8 % of node-positive patients were diagnosed with grade 2 disease. • Synchronous endometrial and ovarian cancer did not affect survival. • Staging lymphadenectomy in G2 patients was associated with improved survival. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
239. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres.
- Author
-
Schwameis, Richard, Fanfani, Francesco, Ebner, Christoph, Zimmermann, Naomi, Peters, Inge, Nero, Camilla, Marth, Christian, Ristl, Robin, Leitner, Katharina, Grimm, Christoph, Oberndorfer, Felicitas, Capasso, Ilaria, Zeimet, Alain G., Polterauer, Stephan, Scambia, Giovanni, Fagotti, Anna, and Concin, Nicole
- Subjects
- *
MOLECULAR diagnosis , *RETROSPECTIVE studies , *TUMOR classification , *COMPARATIVE studies , *ENDOMETRIAL tumors , *SURVIVAL analysis (Biometry) , *DESCRIPTIVE statistics , *PROGRESSION-free survival , *OVERALL survival - Abstract
Recently, the new 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer (EC) critically integrating new pathological and molecular features was published. The present study evaluated the clinical impact of the new 2023 FIGO staging system by comparing it to the previous 2009 system. This is an international, pooled retrospective study of 519 EC patients who underwent primary treatment (and molecular characterisation) at three European Society of Gynaecological Oncology (ESGO) accredited centres in Austria/Italy. Patients were categorised according to the 2009 and the 2023 FIGO staging systems. Stage shifts were analysed and (sub)stage specific 5-year progression-free (PFS) and overall survival (OS) rates were calculated and compared. Different statistical tests were applied to evaluate the prognostic precision of the two FIGO staging systems and to compare them to each other. (Sub)stage shifts occurred in 143/519 (27.6%) patients: 123 upshifts (23.7%) and 20 (3.9%) downshifts. 2023 FIGO staging system identified a stage I cohort with a notably higher 5-year PFS rate compared to 2009 (93.0% versus 87.4%, respectively). For stage II disease, the 5-year PFS rate was similar in the 2023 and the 2009 FIGO staging systems (70.2% versus 71.2%, respectively). The two new molecularly defined 2023 FIGO substages IAm POLEmut and IICm p53abn displayed distinct, particularly favourable and adverse oncologic outcomes within early stage disease, respectively. A remarkably lower 5-year PFS rate for stage III patients was revealed in the 2023 FIGO staging system compared to 2009 (44.4% versus 54.1%, respectively). All applied statistical tests confirmed a more accurate prediction of PFS and OS by the 2023 FIGO staging system compared to 2009. The new 2023 FIGO stating system led to a substantial stage shift in about one quarter of patients leading to a higher prognostic precision. In early stage disease, the new substages added further prognostic granularity and identified treatment relevant subgroups. [Display omitted] • A substantial stage shift occurred between the 2009 and 2023 FIGO staging systems. • The 2023 FIGO staging system has an improved prognostic precision compared to 2009. • New 2023 FIGO substages in early stage disease add further prognostic granularity. • New molecularly defined FIGO substages identify patients with distinct outcomes. • 2023 FIGO substages in early stage disease identify treatment-relevant subgroups. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
240. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
- Author
-
Guan, Jun, Darb-Esfahani, Silvia, Richter, Rolf, Taube, Eliane T., Ruscito, Ilary, Mahner, Sven, Woelber, Linn, Prieske, Katharina, Concin, Nicole, Vergote, Ignace, Van Nieuwenhuysen, Els, Achimas-Cadariu, Patriciu, Glajzer, Joanna, Woopen, Hannah, Stanske, Mandy, Kulbe, Hagen, Denkert, Carsten, Sehouli, Jalid, and Braicu, Elena Ioana
- Subjects
- *
VASCULAR endothelial growth factor receptors , *OVARIAN cancer , *VASCULAR endothelial growth factors , *PROTHROMBIN - Abstract
Objective: The impact of angiogenesis on long-term survival of high-grade serous ovarian cancer (HGSOC) patients remains unclear. This study investigated whether angiogenic markers correlated with 5-year progression-free survival (PFS) in a large cohort of matched advanced HGSOC tissue samples. Methods: Tumor samples from 124 primary HGSOC patients were retrospectively collected within the Tumor Bank Ovarian Cancer (http://www.toc-network.de). All patients were in advanced stages (FIGO stage III–IV). No patient had received anti-angiogenesis therapy. The cohort contains 62 long-term survivors and 62 controls matched by age and post-surgical tumor residuals. Long-term survivors were defined as patients with no relapse within 5 years after the end of first-line chemotherapy. Controls were patients who suffered from first relapse within 6–36 months after primary treatment. Samples were assessed for immunohistochemical expression of vascular endothelial growth factor (VEGF) A and VEGF receptor 2 (VEGFR2). Expression profiles of VEGFA and VEGFR2 were compared between the two groups. Results: Significant correlation between VEGFA and VEGFR2 expression was observed (p < 0.0001, Spearman coefficient 0.347). A high expression of VEGFR2 (VEGFR2high) was found more frequently in long-term survivors (77.4%, 48/62) than in controls (51.6%, 30/62, p = 0.001), independent of FIGO stage and VEGFA expression in multivariate analysis (p = 0.005). Also, VEGFR2high was found the most frequently in women with PFS ≥ 10 years (p = 0.001) among all 124 patients. However, no significant association was detected between VEGFA expression and 5-year PFS (p = 0.075). Conclusions: VEGFR2 overexpression significantly correlated with long-term PFS in HGSOC patients, independent of age, FIGO stage, tumor residual and VEGFA expression. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
241. The genetic landscape of 87 ovarian germ cell tumors.
- Author
-
Van Nieuwenhuysen, Els, Busschaert, Pieter, Neven, Patrick, Han, Sileny N., Moerman, Philippe, Liontos, Michalis, Papaspirou, Maria, Kupryjanczyk, Jolanta, Hogdall, Claus, Hogdall, Estrid, Oaknin, Ana, Garcia, Angel, Mahner, Sven, Trillsch, Fabian, Cibula, David, Heitz, Florian, Concin, Nicole, Speiser, Paul, Salvesen, Helga, and Sehouli, Jalid
- Subjects
- *
GERM cell tumors , *TUMORS , *EXOMES , *CANCER , *TERATOMA - Abstract
Abstract Background Ovarian germ cell tumors (OGCT) are rare gynecological neoplasms, mostly affecting children and young women. The underlying molecular genetic background of these tumors is poorly characterized. Methods We analyzed somatic copy number aberration (CNA) profiles in 87 OGCT tumors and performed whole exome sequencing (WES) on 24 OGCT tumor and matched germline samples to further elucidate their molecular genetic landscape. Results The overall mutation rate was very low in OGCT compared to other human cancers, with an average of 0.05 mutations per Mb, consistent with their embryological origin. We identified recurrent mutations in KIT and KRAS , while CNA profiling revealed frequent focal amplifications affecting PIK3CA and AKT1 in yolk sac tumors, recurrent focal deletions affecting chromosomal regions 1p36.32, 2q11.1, 4q28.1, 5p15.33, 5q11.1 and 6q27, as well as gains in chromosome 12p that were present in all tumors, except for pure immature teratomas. Conclusion We here present the first whole exome sequencing data and to our knowledge the largest CNA study in OGCT. We confirmed that earlier reported KIT mutations were frequent in dysgerminomas and mixed forms with a dysgerminoma component, whereas chromosome 12p gains were present in all histological subtypes except pure immature teratomas. We detected recurrent KRAS mutations, recurrent focal deletions and an enrichment in the PI3K / AKT / PTEN pathway in yolk sac tumors. Several of these aberrations involve targetable pathways, offering novel treatment modalities for OGCT. Highlights • Ovarian germ cell tumors represent a group of histologically different phenotypes that affect children and young adults. • They are characterized by a low mutation rate and very few recurrent somatic mutations. • 12p gain is the most frequent copy number aberration, except in immature teratomas. • PI3K/AKT/PTEN pathway seems enriched in yolk sac tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
242. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
- Author
-
Vergote, Ignace, von Moos, Roger, Manso, Luis, Van Nieuwenhuysen, Els, Concin, Nicole, and Sessa, Cristiana
- Subjects
- *
OVARIAN cancer , *OVARIAN cancer treatment , *ANTIMITOTIC agents , *PLATINUM , *CANCER chemotherapy , *THERAPEUTICS - Abstract
Background Tumor Treating Fields (TTFields) are an anti-mitotic therapy comprising continuous delivery of low-intensity alternating electric fields at intermediate frequencies to the tumor region by a home-use medical device. Methods The INNOVATE (EF-22) Study was a phase 2, single arm clinical trial, which tested the safety and efficacy of TTFields (200 kHz) in combination with weekly paclitaxel (weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day-cycle; starting dose 80 mg/m 2 ) in 31 patients with recurrent, platinum-resistant ovarian carcinoma. The primary endpoint was safety and secondary endpoints included OS, PFS and RR. Results Median age was 60 (range: 45–77), 24 patients (77%) had serous histology, 16 patients (52%) ECOG score 0 and 15 (48%) ECOG 1, the median number of prior chemotherapy lines was 4 (range: 1–11). All patients received prior platinum-based chemotherapy and 30 (97%) received prior taxanes. No serious adverse events related to TTFields were reported. There was no increase in grade 3–4 adverse events compared to the frequency of such events reported in the literature with single agent weekly paclitaxel. Twenty-six patients (84%) had the expected TTFields-related dermatitis but only one patient permanently discontinued TTFields due to dermatitis. The median PFS was 8.9 months, 7 patients (25%) had partial response and the clinical benefit rate was 71%. The median overall survival was not reached: the one-year survival rate was 61%. Conclusion TTFields combined with weekly paclitaxel were safe in platinum-resistant recurrent ovarian cancer and warrants evaluation in a randomized phase 3 trial. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
243. Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients– A study of the OVCAD consortium.
- Author
-
Gostner, Johanna M., Obermayr, Eva, Braicu, Ioana E., Concin, Nicole, Mahner, Sven, Vanderstichele, Adriaan, Sehouli, Jalid, Vergote, Ignace, Fuchs, Dietmar, and Zeillinger, Robert
- Subjects
- *
INDOLEAMINE 2,3-dioxygenase , *NEOPTERIN , *TRYPTOPHAN , *GYNECOLOGIC oncology ,OVARIAN cancer patients - Abstract
Objective Circulating tumor cells (CTCs) may represent a chronic stimulus for the immune system. In the present study we investigated the potential association of CTCs, the immune activation marker neopterin, and the ratio of kynurenine to tryptophan (Kyn/Trp) as a measure for tryptophan breakdown. Methods Neopterin, tryptophan and kynurenine levels were measured in plasma samples from patients with benign gynecological diseases ( n = 65) and with primary advanced epithelial ovarian cancer (EOC) at diagnosis ( n = 216) and six months after adjuvant platinum-based chemotherapy ( n = 45) by an enzyme-linked immunosorbent assay and high performance liquid chromatography. The presence of CTCs had been assessed in a previous study by qPCR-based analysis of CTC-related transcripts in the blood. The respective plasma levels in EOC and benign samples were compared using a two-tailed Chi 2 or Fisher's exact test. The associations of the analytes and Kyn/Trp with clinicopathological parameters, platinum-sensitivity, and the presence of CTC-related transcripts were assessed using a two-sided t -test. Associations with patient outcome were evaluated using Cox regression analysis. Results In EOC, elevated Kyn/Trp and neopterin levels were associated with advanced disease, peritoneal carcinomatosis, ascites, sub-optimal debulking, poor response to therapy and worse outcome. Likewise, neopterin and Kyn/Trp were elevated in CTC-positive patients, both at diagnosis and at follow-up in platinum-sensitive disease. Conclusions We observed concomitant alterations of CTCs and immune system related biomarkers suggesting that immune responses along with increase of neopterin and Kyn/Trp concentrations are not necessarily only located at the site of the tumor, but may also go on in the circulation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
244. AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer - a retrospective multi-centre study.
- Author
-
Seebacher, Veronika, Polterauer, Stephan, Reinthaller, Alexander, Koelbl, Heinz, Achleitner, Regina, Berger, Astrid, and Concin, Nicole
- Subjects
- *
ABO blood group system , *RH factor , *CARCINOGENESIS , *OVARIAN epithelial cancer , *ADENOCARCINOMA , *DISEASE risk factors - Abstract
Background: AB0 blood groups and Rhesus factor expression have been associated with carcinogenesis, response to treatment and tumor progression in several malignancies. The aim of the present study was to test the hypothesis that AB0 blood groups and Rhesus factor expression are associated with clinical outcome in patients with epithelial ovarian cancer (EOC).Methods: AB0 blood groups and Rhesus factor expression were evaluated in a retrospective multicenter study including 518 patients with EOC. Their association with patients' survival was assessed using univariate and multivariable analyses.Results: Neither AB0 blood groups nor Rhesus factor expression were associated with clinico-pathological parameters, recurrence-free, cancer-specific, or overall survival. In a subgroup of patients with high-grade serous adenocarcinoma, however, blood groups B and AB were associated with a better 5-year cancer-specific survival rate compared to blood groups A and 0 (60.3 ± 8.6% vs. 43.8 ± 3.6%, p = 0.04). Yet, this was not significant in multivariable analysis.Conclusions: AB0 blood groups and Rhesus factor expression are both neither associated with features of biologically aggressive disease nor clinical outcome in patients with EOC. Further investigation of the role of the blood group B antigen on cancer-specific survival in the subgroup of high-grade serous should be considered. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
245. UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in platinum-resistant ovarian cancer (585).
- Author
-
Richardson, Debra, Marth, Christian, Banerjee, Susana, Hays, John, Arend, Rebecca, Tseng, Jill, Cibula, David, Fidalgo, Jose Alejandro Perez, Savarese, Antonella, Madry, Radoslaw, Pothuri, Bhavana, Coleman, Robert, Monk, Bradley, Mirza, Mansoor, Ray-Coquard, Isabelle, Bernardo, Patricia, Putiri, Emily, Shahverdyan, Azniv, Burger, Robert, and Concin, Nicole
- Subjects
- *
OVARIAN cancer , *IMMUNOGLOBULINS , *DRUGS - Published
- 2022
- Full Text
- View/download PDF
246. LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034).
- Author
-
Oaknin, Ana, Backes, Floor, Nieuwenhuysen, Els Van, Eskander, Ramez, González-Martín, Antonio, Makker, Vicky, Marth, Christian, Patel, Manish, Penson, Richard, Redondo, Andrés, Pérez, Maria Jesús Rubio, Hamilton, Erika, Concin, Nicole, McNees, Alexander, Wride, Kenton, Lepley, Denise, Dusek, Rachel, Cameron, Terri, and Pignata, Sandro
- Subjects
- *
PROGRAMMED cell death 1 receptors , *GYNECOLOGIC cancer , *OVARIAN cancer , *CERVICAL cancer , *NIVOLUMAB - Abstract
Objectives: Lucitanib is a potent, selective inhibitor of the tyrosine kinases VEGFR1-3, PDGFRα/ß, and FGFR1-3 that is being investigated in combination with the programmed cell death receptor 1 (PD-1) inhibitor nivolumab in four recurrent gynecologic malignancies (cervical, endometrial, ovarian, and ovarian/endometrial clear-cell cancers) in an ongoing phase II study, using a Simon's two-stage design. To maximize lucitanib exposure and potential clinical benefit of the combination, individualized lucitanib dose titration is utilized. We presented initial data from the cervical cancer cohort. Methods: Patients with metastatic or recurrent cervical cancer of squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma histology, who received ≥1 prior platinum-based chemotherapy regimen, with or without bevacizumab, were enrolled. Prior treatment with a PD-1 or programmed cell death ligand-1 (PD-L1) inhibitor was prohibited. All patients-initiated treatment with lucitanib 6 mg orally once daily (QD) + nivolumab 480 mg intravenously every 28 days. Lucitanib dose was escalated from 6 mg to 8 mg and up to 10 mg QD in patients who met safety-based titration criteria. Tumor response was assessed by investigators per RECIST v1.1. Data cut-off was September 1, 2021. Results: Twenty patients have been treated to date (median treatment duration: 85 days, range: 1-343+); 15 (75%) remain on treatment (13 remain on the combination and two on nivolumab monotherapy). Eleven (55%) patients received ≥2 prior anticancer regimens; nine (45%) had prior bevacizumab. To date, 17 (85%) patients have completed ≥1 cycle; two patients have escalated lucitanib to a dose of 8 mg, and three to the maximum dose of 10 mg. The most frequent anygrade treatment-emergent adverse events (TEAEs) have been hypertension (n =13, 65%), decreased appetite (n =11, 55%), asthenia/fatigue (n =10, 50%), and nausea (n =10, 50%). The most frequent grade ≥3 TEAE has been hypertension (n =4, 20%). Three (15%) patients discontinued lucitanib due to a related TEAE (colonic fistula, hypertension, and proteinuria). As of the data cut-off, 17 patients had at least one post-baseline tumor assessment, with four confirmed partial responses (PRs), eight patients with stable disease (7 remain ongoing), and five patients with the best response of progressive disease reported. The durations of PR range from 1.8+ to 9.3+ months. Of the four responding patients, three had received prior bevacizumab. Conclusions: Promising signs of antitumor activity in patients with metastatic or recurrent cervical cancer were noted in this initial analysis. Toxicity has been manageable and is consistent with that previously reported for lucitanib and nivolumab, and other agents of both classes. Having met Simon's two-stage stage I requirements (≥3 confirmed responses), study accrual continues in stage II of the cervical cancer cohort. Additional and more mature data, including biomarker analyses, will be presented at the meeting. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
247. Mineral oil in human tissues, Part I: Concentrations and molecular mass distributions.
- Author
-
Barp, Laura, Kornauth, Christoph, Wuerger, Tanja, Rudas, Margaretha, Biedermann, Maurus, Reiner, Angelika, Concin, Nicole, and Grob, Koni
- Subjects
- *
MINERAL oils , *TISSUE engineering , *MOLECULAR weights , *HYDROCARBONS , *AROMATIC compounds , *ALKANES - Abstract
Of 37 subjects aged 25–91 y (mean 67 y), mineral oil hydrocarbons were measured in subcutaneous abdominal fat tissue, mesenteric lymph nodes (MLN), spleen, liver and lung, for some of them also in kidney, heart and brain. No mineral oil aromatic hydrocarbons (MOAH) were detected. The mean concentration of mineral oil saturated hydrocarbons (MOSH) in the mesenteric lymph nodes was 223 mg/kg, in liver 131 mg/kg, in fat tissue 130 mg/kg, in spleen 93 mg/kg and in lung 12 mg/kg. They were clearly lower in kidney, heart and brain. The maxima, found in MLN and spleen, were 1390 and 1400 mg/kg, respectively. For a quarter of the subjects a total amount of MOSH in the body above 5 g was calculated. The MOSH composition in the fat tissue and the MLN appeared virtually identical and varied little between the subjects. It was centered on the n -alkanes C 23 –C 24 , ranged from C 16 to C 35 and included hydrocarbons of plant origin. The MOSH in spleen and liver had almost the same composition for a given subject, but varied somewhat between subjects. They were centered between C 25 and C 27 , ranged from C 18 to beyond C 45 and were without hydrocarbons of plant origin. Part of the MOSH seem to be strongly accumulated, resulting in far higher concentrations in human tissues related to exposure than observed in shorter term animal experiments. The composition of the accumulated MOSH does not support that Class I mineral oils, sometimes termed “food grade”, are less accumulated in the human body than Class II and III oils, which questions the present classification. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
248. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer
- Author
-
Polterauer, Stephan, Zhou, Qin, Grimm, Christoph, Seebacher, Veronika, Reinthaller, Alexander, Hofstetter, Gerda, Concin, Nicole, Leitao, Mario M., Barakat, Richard R., Abu-Rustum, Nadeem R., and Iasonos, Alexia
- Subjects
- *
ENDOMETRIAL cancer , *NOMOGRAPHY (Mathematics) , *COHORT analysis , *MEDICAL statistics , *PREDICTION models , *MEDICAL databases - Abstract
Abstract: Objectives: Nomograms are predictive models that provide the overall probability of a specific outcome. Nomograms have shown better individual discrimination than currently used staging systems in numerous tumor entities. Recently, a nomogram for predicting overall survival (OS) in women with endometrial cancer was introduced by Memorial Sloan–Kettering Cancer Center (MSKCC). The aim of this study was to test the validity of the MSKCC endometrial cancer nomogram using an independent, external patient cohort. Methods: The MSKCC nomogram is based on five readily available clinical characteristics. A multi-institutional endometrial cancer database was used to test the nomogram''s validity. All consecutive patients treated for endometrial cancer between December 1995 and May 2011 and who had all nomogram variables documented were identified for analysis. Results: Seven hundred sixty-five eligible patients were identified and used for external validation analysis. In the Austrian patient cohort, median OS was 134months, and 3-year and 5-year OS rates were 83.8% (95% CI, 80.6–86.5%) and 77.2% (95% CI, 43.5–80.5%), respectively. The nomogram concordance index was 0.71 (SE=0.017; 95% CI, 0.68–0.74). The correspondence between the actual OS and the nomogram predictions suggests a good calibration of the nomogram in the validation cohort. Conclusion: The MSKCC endometrial cancer nomogram was externally validated and was shown to be generalizable to a new and independent patient population. The nomogram provides a more individualized and accurate estimation of OS for patients diagnosed with endometrial cancer following primary therapy. The nomogram can be used for counseling patients more accurately and for better stratifying patients for clinical trials. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
249. Relevance of gamma-glutamyltransferase – a marker for apoptotic balance – in predicting tumor stage and prognosis in cervical cancer
- Author
-
Polterauer, Stephan, Hofstetter, Gerda, Grimm, Christoph, Rahhal, Jasmin, Mailath-Pokorny, Mariella, Kohl, Maria, Concin, Nicole, Tempfer, Clemens, Marth, Christian, and Reinthaller, Alexander
- Subjects
- *
CERVICAL cancer , *TRANSFERASES , *BIOMARKERS , *APOPTOSIS , *TUMOR classification , *DISEASE incidence , *DISEASE progression , *EPIDEMIOLOGY of cancer , *PROGNOSIS - Abstract
Abstract: Introduction: Recent large epidemiologic population-based studies identified gamma-glutamyltransferase (GGT) as a marker for increased cervical cancer incidence. Furthermore, high levels of GGT seem to increase the risk of progression of high-grade cervical dysplasia to invasive carcinoma. Therefore, we evaluated the association between pre-therapeutic serum GGT levels, tumor stage and prognosis in patients with cervical cancer. Materials and methods: In this multi-center trial, pre-therapeutic GGT levels were examined in 692 patients with cervical cancer. GGT levels were correlated with clinico-pathological parameters. Patients were assigned to previously described GGT risk groups and uni- and multivariable survival analyses were performed. Results: GGT serum levels were associated with FIGO stage (p <0.0001) and age (r=0.2, p <0.0001) but not with lymph node involvement (p =0.85), and histological type (p =0.98). High-risk GGT group affiliation (p =0.01 and p <0.0001) was associated with poor disease-free and overall survival in a univariate analysis, but not in a multivariable Cox-regression model (p =0.59 and p =0.171). We further investigated the association between prognosis and GGT and observed a linear correlation between GGT and prognosis. Therefore we were not able to identify a clear prognostic cut-off value for GGT in patients with cervical cancer. Conclusions: High GGT – a marker for apoptosis and cervical cancer risk – is associated with advanced tumor stage in patients with cervical cancer. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
250. Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer.
- Author
-
Zeimet, Alain G., Reimer, Daniel, Schwentner, Lukas, Fuchs, Dietmar, Wolf, Dominik, Fuith, Lothar C., Fiegl, Heidi, Doppler, Wolfgang, Concin, Nicole, Daxenbichler, Günter, and Marth, Christian
- Subjects
- *
URINARY incontinence , *NEOPTERIN , *MESSENGER RNA , *CANCER patients , *CANCER education - Abstract
The main objective of the present investigation was to study the urinary neopterin excretion in the context of the activation of the adaptive cellular immune system at the tumor site. For this purpose, we compared pre-treatment urinary neopterin levels measured in 92 ovarian cancer patients, with intratumoral levels of mRNA transcripts from factors either involved in the adaptive antitumor immune defense (CD3, IFN-γ, IRF-1, IRF-2, SOCS1 and iNOS) or immune tolerance (FoxP3). This study did not reveal an association between urinary neopterin and one of these investigated 'on tumor site transcripts'. From all the factors reflecting the magnitude of the local adaptive antitumor response, intratumoral IRF-1 expression above the edge of the 25th percentile was found to predict most reliably favorable progression-free (median 34 months vs. 10 months; p < 0.001) and overall (median 52 months vs. 16 months; p < 0.001) survival. In contrast, pre-treatment urinary neopterin excretion above 275 μmol/mol creatinine, which indicates an unspecific activation of the innate immune system, was associated with a very poor overall survival with a median of only 11 months when compared with a median overall survival of 40 months in patients with lower urinary neopterin excretion ( p = 0.021). Interestingly, the considerable survival benefit in patients with high IRF-1-expressing cancers was completely abrogated as well for progression-free as for overall survival when urinary neopterin concentrations were found to be concomitantly elevated. These findings demonstrate that in ovarian carcinomas the unspecific 'cancer-related inflammation' contributes to a significant subversion of the adaptive antitumor immune defense mounted at the tumor site. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.